



(51) International Patent Classification:

C07D 403/14 (2006.01) *A61K 31/4178* (2006.01)
C07D 405/14 (2006.01) *A61K 31/4184* (2006.01)
C07D 487/04 (2006.01) *A61K 31/4188* (2006.01)
C07D 491/044 (2006.01) *A61P 31/14* (2006.01)
C07D 491/052 (2006.01)

(21) International Application Number:

PCT/US2009/033380

(22) International Filing Date:

6 February 2009 (06.02.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/028,277 13 February 2008 (13.02.2008) US

(71) Applicant (for all designated States except US): **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543-4000 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **BACHAND, Carol** [CA/CA]; 119 Place Mercure, Candiac, Québec J5R 1B1 (CA). **BELEMA, Makonen** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **DEON, Daniel H.** [CA/CA]; 401-4905 Av. Colomb, Brossard, Québec J4Z 3T2 (CA). **GOOD, Andrew C.** [US/US]; 52 High Hill Road, Wallingford, Connecticut 06492 (US). **GOODRICH, Jason** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).

JAMES, Clint A. [CA/CA]; 500 Boulevard Quinn, Longueuil, Québec J4H 2N4 (CA). **LAVOIE, Rico** [CA/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **LOPEZ, Omar D.** [AR/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **MARTEL, Alain** [CA/CA]; 29 Rue Monette, Delson, Québec J5B 1G8 (CA). **MEANWELL, Nicholas A.** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **NGUYEN, Van N.** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **ROMINE, Jeffrey Lee** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **RUEDIGER, Edward H.** [CA/CA]; 133 St. Charles, Greenfield Park, Québec J4V 2K3 (CA). **SNYDER, Lawrence B.** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **ST. LAURENT, Denis R.** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **YANG, Fukang** [CN/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **LANGLEY, David R.** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **WANG, Gan** [US/US]; c/o Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **HAMANN, Lawrence G.** [US/US]; 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

[Continued on next page]

(54) Title: HEPATITIS C VIRUS INHIBITORS



(57) **Abstract:** The present disclosure relates to compounds of structure (I), compositions and Methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.



(74) **Agents:** MINGO, Pamela A. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, New Jersey 08543-4000 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))